Orexigen Therapeutics, Inc. (OREX) is a publicly traded company in the Unknown sector. Across all available filings, 42 corporate insiders have executed 947 transactions totaling $219.2M, demonstrating a bullish sentiment with $125.6M in net insider flow. The most recent transaction on Mar 15, 2018 involved a sale of 1,694 shares valued at $407.
No significant insider buying has been recorded for OREX in the recent period.
No significant insider selling has been recorded for OREX in the recent period.
Based on recent SEC filings, insider sentiment for OREX is bullish with an Insider Alignment Score of 79/100 and a net flow of $125.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Orexigen Therapeutics, Inc. (OREX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 42 insiders are actively trading OREX stock, having executed 947 transactions in the past 90 days. The most active insider is Kathleen K. Schoemaker (Executive), who has made 48 transactions totaling $25.9M.
Get notified when executives and directors at OREX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Mar 15, 2018 | A. Moglia Stephen | Executive | Sale | 1,694 | $0.24 | $407 | |
| May 31, 2017 | R. Cannell Thomas | Executive | Award | 2,119 | $1.55 | $3.3K | |
| May 31, 2017 | A. Keyes Jason | Executive | Award | 557 | $1.55 | $863 | |
| May 31, 2017 | P. Lynch Thomas | Executive | Award | 1,704 | $1.55 | $2.6K | |
| May 31, 2017 | Narachi Michael | Executive | Award | 626 | $1.55 | $970 | |
| Dec 19, 2016 | A. Moglia Stephen | Executive | Sale | 800 | $1.96 | $1.6K | |
| Nov 30, 2016 | R. Cannell Thomas | Executive | Award | 291 | $1.67 | $486 | |
| Nov 30, 2016 | A. Keyes Jason | Executive | Award | 291 | $1.67 | $486 | |
| Nov 30, 2016 | Narachi Michael | Executive | Award | 802 | $1.67 | $1.3K | |
| May 31, 2016 | R. Cannell Thomas | Executive | Award | 9,632 | $0.34 | $3.3K | |
| May 31, 2016 | Narachi Michael | Executive | Award | 8,777 | $0.34 | $3.0K | |
| Nov 30, 2015 | Narachi Michael | Executive | Award | 1,761 | $2.03 | $3.6K | |
| Nov 30, 2015 | R. Cannell Thomas | Executive | Award | 5,091 | $2.03 | $10.3K | |
| Nov 30, 2015 | Klassen Preston | Executive | Award | 4,170 | $2.03 | $8.5K | |
| May 30, 2015 | Klassen Preston | Executive | Award | 1,860 | $4.17 | $7.8K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 279 | $172.4M | 77.5% |
Sale(S) | 514 | $46.8M | 21.0% |
Exercise(M) | 50 | $3.0M | 1.3% |
Award(A) | 23 | $203.5K | 0.1% |
Payment(F) | 2 | $4.7K | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Other(J) | 17 | $0 | 0.0% |
Conversion(C) | 60 | $0 | 0.0% |
Insiders at Orexigen Therapeutics, Inc. are accumulating shares at an accelerated pace. With 42 insiders making 947 transactions totaling $172.4M in purchases versus $46.8M in sales, the net buying activity of $125.6M signals strong executive confidence. Kathleen K. Schoemaker (Executive) leads the buying activity with $25.9M in transactions across all time.